Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.35 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.35 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2398466 | 0.76 | KDM4E (0.34) | KMT2AKDM4E | |
| SCHEMBL797323 | 0.68 | PIK3CB (0.34) | APP | |
| SCHEMBL31194479 | 0.67 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL256376 | 0.67 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL7920028 | 0.65 | CCR1 (0.43) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL2067409 | 0.65 | SLC9A1 (0.36) | — | |
| SCHEMBL3303776 | 0.64 | HSD17B10 (0.46) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL16617428 | 0.64 | — | — | |
| SCHEMBL31752039 | 0.64 | APP (0.47) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL30478722 | 0.64 | APP (0.40) | PI4KAPI4K2BPI4K2API4KBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310413-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A MALT1 INHIBITOR AND A MIXTURE OF POLYETHYLENE GLYCOL WITH A FATTY ACID | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-05 | — | — | US | claimed |
| CN-115884773-A | Pharmaceutical preparation | 詹森药业有限公司 | 2023-03-31 | — | — | CN | claimed |
| CN-115210567-A | Methods of assessing efficacy of MALT1 inhibitors using NF-KB translocation assays | 詹森药业有限公司 | 2022-10-18 | — | — | CN | claimed |
| EP-4062175-A1 | METHODS FOR ASSESSING EFFICACY OF MALT1 INHIBITORS USING AN NF-KB TRANSLOCATION ASSAY | Janssen Pharmaceutica NV (BE) | 2022-09-28 | — | — | EP | claimed |
| EP-4061966-A1 | NF-KB REGULATED GENE EXPRESSION ASSAY FOR ASSESSING EFFICACY OF MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2022-09-28 | — | — | EP | claimed |
| CN-114981453-A | NF-KB regulated gene expression assay for assessing efficacy of MALT1 inhibitors | 詹森药业有限公司 | 2022-08-30 | — | — | CN | claimed |
| US-20220175760-A1 | PHARMACEUTICAL FORMULATIONS | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-09 | — | — | US | claimed |
| CN-113473971-A | Pharmaceutical formulations | 詹森药业有限公司 | 2021-10-01 | — | — | CN | claimed |
| WO-2021099609-A1 | METHODS FOR ASSESSING EFFICACY OF MALT1 INHIBITORS USING AN NF-KB TRANSLOCATION ASSAY | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-27 | — | — | WO | claimed |
| WO-2021099612-A1 | NF-KB REGULATED GENE EXPRESSION ASSAY FOR ASSESSING EFFICACY OF MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-27 | — | — | WO | claimed |
| US-20210155990-A1 | NF-KB REGULATED GENE EXPRESSION ASSAY FOR ASSESSING EFFICACY OF MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-27 | — | — | US | claimed |
| US-20210156865-A1 | METHODS FOR ASSESSING EFFICACY OF MALT1 INHIBITORS USING AN NF-KB TRANSLOCATION ASSAY | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-27 | — | — | US | claimed |
| CN-107074822-B | Triazole compounds as T-type calcium channel blockers | 爱杜西亚药品有限公司 | 2020-01-03 | — | — | CN | claimed |
| EP-3558969-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2019-10-30 | — | — | EP | claimed |
| US-10246426-B2 | Triazole compounds as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-04-02 | — | — | US | claimed |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | claimed |
| EP-3194374-B1 | TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-08-01 | — | — | EP | claimed |
| WO-2018119036-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2018-06-28 | — | — | WO | claimed |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN-CILAG (FR) | 2018-06-21 | — | — | US | claimed |
| CN-113473971-B | Pharmaceutical formulations | 詹森药业有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20230414629-A1 | MATERIALS AND METHODS OF TREATING CANCER | MONOPTEROS THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230310413-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A MALT1 INHIBITOR AND A MIXTURE OF POLYETHYLENE GLYCOL WITH A FATTY ACID | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-05 | — | — | US | disclosed |
| EP-4243812-A1 | MATERIALS AND METHODS OF TREATING CANCER | Monopteros Therapeutics, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| CN-116710089-A | Materials and methods for treating cancer | 莫诺泰罗斯疗法公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20230235077-A1 | MATERIALS AND METHODS OF TREATING CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-27 | — | — | US | disclosed |
| CN-115884773-A | Pharmaceutical preparation | 詹森药业有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-11571427-B2 | Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment | THE GENERAL HOSPITAL CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| CN-115210567-A | Methods of assessing efficacy of MALT1 inhibitors using NF-KB translocation assays | 詹森药业有限公司 | 2022-10-18 | — | — | CN | disclosed |
| EP-4062175-A1 | METHODS FOR ASSESSING EFFICACY OF MALT1 INHIBITORS USING AN NF-KB TRANSLOCATION ASSAY | Janssen Pharmaceutica NV (BE) | 2022-09-28 | — | — | EP | disclosed |
| CN-114981453-A | NF-KB regulated gene expression assay for assessing efficacy of MALT1 inhibitors | 詹森药业有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-11401272-B2 | Heterocyclic compounds as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-08-02 | — | — | US | disclosed |
| US-20220175760-A1 | PHARMACEUTICAL FORMULATIONS | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-09 | — | — | US | disclosed |
| WO-2022101676-A1 | MATERIALS AND METHODS OF TREATING CANCER | MONOPTEROS THERAPEUTICS,INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2021262969-A1 | MATERIALS AND METHODS OF TREATING CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2021-12-30 | — | — | WO | disclosed |
| CN-113473971-A | Pharmaceutical formulations | 詹森药业有限公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-107660205-B | Heterocyclic compounds as LSD1 inhibitors | 因赛特公司 | 2021-08-27 | — | — | CN | disclosed |
| US-20210155990-A1 | NF-KB REGULATED GENE EXPRESSION ASSAY FOR ASSESSING EFFICACY OF MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-27 | — | — | US | disclosed |
| WO-2021099609-A1 | METHODS FOR ASSESSING EFFICACY OF MALT1 INHIBITORS USING AN NF-KB TRANSLOCATION ASSAY | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-27 | — | — | WO | disclosed |
| US-20210156865-A1 | METHODS FOR ASSESSING EFFICACY OF MALT1 INHIBITORS USING AN NF-KB TRANSLOCATION ASSAY | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-27 | — | — | US | disclosed |
| US-10954214-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-23 | — | — | US | disclosed |
| US-20210052596-A1 | TARGETING THE CBM SIGNALOSOME COMPLEX INDUCES REGULATORY T CELLS TO INFLAME THE TUMOR MICROENVIRONMENT | THE GENERAL HOSPITAL CORPORATION (US) | 2021-02-25 | — | — | US | disclosed |
| US-20200392143-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | INCYTE CORPORATION | 2020-12-17 | — | — | US | disclosed |
| EP-3731848-A1 | TARGETING THE CBM SIGNALOSOME COMPLEX INDUCES REGULATORY T CELLS TO INFLAME THE TUMOR MICROENVIRONMENT | The General Hospital Corporation (US) | 2020-11-04 | — | — | EP | disclosed |
| CN-111770759-A | Targeting the CBM-signalosome complex to induce regulatory T cells to inflame the tumor microenvironment | 通用医疗公司 | 2020-10-13 | — | — | CN | disclosed |
| US-10800779-B2 | Heterocyclic compounds as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3626720-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | Incyte Corporation (US) | 2020-03-25 | — | — | EP | disclosed |
| CN-107074822-B | Triazole compounds as T-type calcium channel blockers | 爱杜西亚药品有限公司 | 2020-01-03 | — | — | CN | disclosed |
| EP-3558969-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2019-10-30 | — | — | EP | disclosed |
| EP-3277689-B1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | INCYTE CORP (US) | 2019-09-04 | — | — | EP | disclosed |
| US-10246426-B2 | Triazole compounds as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-04-02 | — | — | US | disclosed |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | disclosed |
| US-20190055250-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | INCYTE CORPORATION | 2019-02-21 | — | — | US | disclosed |
| EP-3194374-B1 | TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-08-01 | — | — | EP | disclosed |
| WO-2018119036-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN-CILAG (FR) | 2018-06-21 | — | — | US | disclosed |
| US-9944647-B2 | Heterocyclic compounds as LSD1 inhibitors | INCYTE CORPORATION (US) | 2018-04-17 | — | — | US | disclosed |
| EP-3277689-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | Incyte Corporation (US) | 2018-02-07 | — | — | EP | disclosed |
| EP-3194374-A1 | TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS | Idorsia Pharmaceuticals Ltd (CH) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016161282-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160289238-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | INCYTE CORPORATION | 2016-10-06 | — | — | US | disclosed |
| WO-2016041892-A1 | TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-03-24 | — | — | WO | disclosed |
| US-9006225-B2 | Stable pharmaceutical composition | ASAHI KASEI PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| EP-2236135-A1 | STABLE PHARMACEUTICAL COMPOSITION | Asahi Kasei Pharma Corporation (JP) | 2010-10-06 | — | — | EP | disclosed |
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20100041725-A1 | STABLE PHARMACEUTICAL COMPOSITION | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | disclosed |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7470807-B2 | Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-12-30 | — | — | US | disclosed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (22 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401272-B2 | Heterocyclic compounds as LSD1 inhibitors | KDM1B, KDM1A, DOT1L | PI4KA 4134/4885PI4K2B 4182/4885PI4K2A 4312/4885 |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | PI4KA 4410/4885PI4K2B 4244/4885PI4K2A 4330/4885 |
| US-20200392143-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, DOT1L | PI4KA 4134/4885PI4K2B 4182/4885PI4K2A 4312/4885 |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | SMYD3, SMYD2, EHMT1 | PI4KA 3660/4885PI4K2B 3993/4885PI4K2A 4037/4885 |
| US-20190055250-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, DOT1L | PI4KA 4134/4885PI4K2B 4182/4885PI4K2A 4312/4885 |
| US-10246426-B2 | Triazole compounds as T-type calcium channel blockers | CACNA1I, CACNA1E, CACNA1G | PI4KA 2340/4885PI4K2B 2479/4885PI4K2A 3026/4885 |
| US-10954214-B2 | Pyrazole derivatives as MALT1 inhibitors | MALT1, PPP3R1, SQSTM1 | PI4KA 1711/4885PI4K2B 1587/4885PI4K2A 1834/4885 |
| US-20210052596-A1 | TARGETING THE CBM SIGNALOSOME COMPLEX INDUCES REGULATORY T CELLS TO INFLAME THE TUMOR MICROENVIRONMENT | CD47, ICOS, LCK | PI4KA 1798/4885PI4K2B 1872/4885PI4K2A 2099/4885 |
| US-20210155990-A1 | NF-KB REGULATED GENE EXPRESSION ASSAY FOR ASSESSING EFFICACY OF MALT1 INHIBITORS | MALT1, NFKBIA, NFKB2 | PI4KA 3607/4885PI4K2B 3658/4885PI4K2A 3851/4885 |
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | PI4KA 3789/4885PI4K2B 4069/4885PI4K2A 3807/4885 |
| US-20230235077-A1 | MATERIALS AND METHODS OF TREATING CANCER | MALT1, CD274, TP53 | PI4KA 1415/4885PI4K2B 1823/4885PI4K2A 1623/4885 |
| US-20230310413-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A MALT1 INHIBITOR AND A MIXTURE OF POLYETHYLENE GLYCOL WITH A FATTY ACID | MALT1, MGAM, MGLL | PI4KA 1557/4885PI4K2B 2209/4885PI4K2A 1799/4885 |
| US-20160289238-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, DOT1L | PI4KA 4134/4885PI4K2B 4182/4885PI4K2A 4312/4885 |
| US-20220175760-A1 | PHARMACEUTICAL FORMULATIONS | TREH, F12, CEL | PI4KA 2776/4885PI4K2B 3254/4885PI4K2A 2961/4885 |
| US-11571427-B2 | Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment | CD47, ICOS, LCK | PI4KA 1798/4885PI4K2B 1872/4885PI4K2A 2099/4885 |
| US-10800779-B2 | Heterocyclic compounds as LSD1 inhibitors | KDM1B, KDM1A, DOT1L | PI4KA 4134/4885PI4K2B 4182/4885PI4K2A 4312/4885 |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | PI4KA 3789/4885PI4K2B 4069/4885PI4K2A 3807/4885 |
| US-20100041725-A1 | STABLE PHARMACEUTICAL COMPOSITION | SLC5A1, SLC5A2, SLC2A9 | PI4KA 4366/4885PI4K2B 3811/4885PI4K2A 3695/4885 |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | MALT1, PPP3R1, SQSTM1 | PI4KA 1711/4885PI4K2B 1587/4885PI4K2A 1834/4885 |
| US-20230414629-A1 | MATERIALS AND METHODS OF TREATING CANCER | MALT1, TP53, RAD1 | PI4KA 1902/4885PI4K2B 2082/4885PI4K2A 2020/4885 |
| US-20210156865-A1 | METHODS FOR ASSESSING EFFICACY OF MALT1 INHIBITORS USING AN NF-KB TRANSLOCATION ASSAY | NFKBIA, MALT1, NFATC1 | PI4KA 3309/4885PI4K2B 3699/4885PI4K2A 3888/4885 |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | PI4KA 3789/4885PI4K2B 4069/4885PI4K2A 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.